ADAG - Company ID 0001818838
Adagene Inc. trades as ADAG. In its fiscal 2025 annual report the company posted revenue of $7.67M, up 7332.8% from the prior year and net income of -$17.61M. This page tracks Adagene Inc. through 170 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 7 fiscal years Adagene Inc.'s revenue grew from $1.51M to $7.67M, a compound annual growth rate of 26.1%. Net profit margin expanded from -1010.2% to -229.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| 6-K | - | 2026-04-17 |
| Prospectus supplement | 424B5 | 2026-04-02 |
| 6-K | - | 2026-04-02 |
| Prospectus supplement | 424B5 | 2026-04-02 |
| 6-K | - | 2026-04-02 |
| 6-K | - | 2026-04-01 |
| 20-F | - | 2026-04-01 |
The largest companies sharing Adagene Inc.'s SEC industry classification (pharmaceutical preparations).
Adagene Inc. reported revenue of $7.67M for fiscal year 2025, an increase of 7332.8% year over year.
In its latest fiscal year Adagene Inc. reported a net loss of $17.61M.